COVID-19: A Chimera of Two Pandemics

Jabbari, Parnian; Jabbari, Forouq; Ebrahimi, Saied; Rezaei, Nima

doi:10.1017/dmp.2020.223

Cited by 38 publications

(25 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The newly emerged SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), is a positive-sense single-stranded RNA (+ssRNA) virus that causes COVID-19 (coronavirus disease 2019), which has been getting global concern since December 2019 [ [1] , [2] , [3] , [4] ]. Coronaviruses belong to the subfamily Coronavirinae , in the family Coronaviridae of the order Nidovirales .…”

Section: Introductionmentioning

confidence: 99%

The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19

et al. 2020

Self Cite

View full text Add to dashboard Cite

Aims The immune response is essential for the control and resolution of viral infections. Following the outbreak of novel coronavirus disease (COVID-19), several immunotherapies were applied to modulate the immune responses of the affected patients. In this review, we aimed to describe the role of the immune system in response to COVID-19. We also provide a systematic review to collate and describe all published reports of the using immunotherapies, including convalescent plasma therapy, monoclonal antibodies, cytokine therapy, mesenchymal stem cell therapy, and intravenous immunoglobulin and their important outcomes in COVID-19 patients. Material and methods A thorough search strategy was applied to identify published research trials in PubMed, Scopus, Medline, and EMBASE from Dec 1, 2019, to May 4, 2020, for studies reporting clinical outcomes of COVID-19 patients treated with immunotherapies along with other standard cares. Key findings From an initial screen of 80 identified studies, 24 studies provided clinical outcome data on the use of immunotherapies for the treatment of COVID-19 patients, including convalescent plasma therapy (33 patients), monoclonal antibodies (55 patients), interferon (31 patients), mesenchymal stem cell therapy (8 patient), and immunoglobulin (63 patients). Except for nine severe patients who died after treatment, most patients were recovered from COVID-19 with improved clinical symptoms and laboratory assessment. Significance Based on the available evidence, it seems that treatment with immunotherapy along with other standard cares could be an effective and safe approach to modulate the immune system and improvement of clinical outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Progressively spreading throughout the world, the novel coronavirus disease 2019 (COVID- 19) is affecting more and more individuals every day. Despite implementing various policies in the service of controlling the crisis by different jurisdictions, many countries initially underestimated the extent of this pandemic, while a few countries are still far from ideal control by mid-2020 (1)(2)(3). Some of the reasons for the current global crisis include commercial globalization and consumer culture (4).…”

Section: Introductionmentioning

confidence: 99%

Emerging Standards and the Hybrid Model for Organizing Scientific Events During and After the COVID-19 Pandemic

Hanaei

Takian

Majdzadeh

et al. 2020

Disaster med. public health prep.

Self Cite

View full text Add to dashboard Cite

Since the beginning of 2020, the COVID-19 pandemic has dramatically influenced almost every aspect of human life. Activities requiring human gatherings have either been postponed, cancelled, or held completely virtually. To supplement lack of in-person contact, people have increasingly turned to virtual settings on-line, advantages of which include increased inclusivity and accessibility and reduction of carbon footprint. However, emerging online technologies cannot fully replace, in-person scientific events. In-person meetings are not susceptible to poor internet connectivity problems, and they provide novel opportunities for socialization, creating new collaborations, and sharing ideas. To continue such activities, a hybrid model for scientific events could be a solution offering both in-person and virtual components. While participants can freely choose the mode of their participation, virtual meetings would most benefit those who cannot attend in-person due to the limitations. In-person portions of meetings should be organized with full consideration of prevention and safety strategies including risk assessment and mitigation, venue and environmental sanitation, participant protection and disease prevention, and promoting the hybrid model. This new way of interaction between scholars can be considered as a part of a resilience system which was neglected previously and should become a part of routine practice in scientific community.

show abstract

“…In December 2019, an outbreak of respiratory disease due to a novel coronavirus (CoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurred first in Wuhan, China; and then rapidly spread globally. The World Health Organization (WHO) named this disease coronavirus disease 2019 (COVID-19) [1][2][3][4][5]. In addition to the respiratory tract symptoms, COVID-19 patients can develop neurological symptoms, including dizziness, headache, impaired consciousness, acute cerebrovascular disease, encephalopathy, ataxia, seizure, peripheral nervous system involvement (taste, smell, and vision impairment such as optic neuritis, and Guillain-Barré syndrome), and nerve pain [6][7][8][9][10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 and Multiple Sclerosis: Predisposition and Precautions in Treatment

Sadeghmousavi

Rezaei

2020

SN Compr. Clin. Med.

Self Cite

View full text Add to dashboard Cite

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to Coronavirus disease 2019 (COVID-19), is not always confined to the respiratory tract, while patients with can develop neurological manifestations. The patients with multiple sclerosis (MS) pose challenges in this pandemic situation, because of the immunosuppressive medications they get and the fact that viral infections may contribute to MS exacerbation and relapses as an environmental factor in genetically predisposed individuals. Herein, possible consequences of COVID-19 which may carry for the MS patients and the underlying mechanisms of its impact are discussed.

show abstract

COVID-19: A Chimera of Two Pandemics

Cited by 38 publications

References 5 publications

The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19

The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19

Emerging Standards and the Hybrid Model for Organizing Scientific Events During and After the COVID-19 Pandemic

COVID-19 and Multiple Sclerosis: Predisposition and Precautions in Treatment

Contact Info

Product

Resources

About